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This study aimed to estimate the extent of ‘overdiagnosis’ of prostate cancer attributable to prostate-specific antigen (PSA) testing in
the Cambridge area between 1996 and 2002. Overdiagnosis was defined conceptually as detection of prostate cancer through PSA
testing that otherwise would not have been diagnosed within the patient’s lifetime. Records of PSA tests in Addenbrookes Hospital
were linked to prostate cancer registrations by NHS number. Differences in prostate cancer registration rates between those
receiving and not receiving prediagnosis PSA tests were calculated. The proportion of men aged 40 years or over with a prediagnosis
PSA test increased from 1.4 to 5.2% from 1996 to 2002. The rate of diagnosis of prostate cancer was 45% higher (rate ratios
(RR)¼1.45, 95% confidence intervals (CI) 1.02–2.07) in men with a history of prediagnosis PSA testing. Assuming average lead times
of 5 to 10 years, 40–64% of the PSA-detected cases were estimated to be overdiagnosed. In East Anglia, from 1996 to 2000, a 1.6%
excess of cases was associated with PSA testing (around a quarter of the 5.3% excess incidence cases observed in East Anglia from
1996 to 2000). Further quantification of the overdiagnosis will result from continued surveillance and from linkage of incidence to
testing in other hospitals.
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A descriptive epidemiological study in East Anglia has shown a 6%
excess of prostate cancer registrations during 1991–2000 relative
to expectations based on pre-1991 trends, coincident with an
increase in prostate-specific antigen (PSA) testing (Pashayan et al,
2006). This increase in PSA testing came not from a formal
screening programme (no such programme existed), but rather
from the increased use of the test for case finding and in the
investigation of men with urological symptoms. It is of interest to
estimate how many of the excess cases are attributable to PSA
testing and how many of these are plausibly classed as over-
diagnosed.
Overdiagnosis is usually defined conceptually as the diagnosis,
as a result of screening, of a cancer usually histologically
confirmed, which would have not achieved clinical significance
during the lifetime of the host had screening not taken place (Paci
et al, 2004). Here, potential overdiagnosis would be attributed
to increased diagnostic testing rather than to screening. The
prevalence of urological symptoms in males increases to high
levels in late middle and old age. In recent years, the advent of PSA
testing has led to a fast and relatively simple diagnostic sequence
for prostate cancer. This may have occasioned diagnosis of the
disease in some elderly men who would not have had such a
diagnosis in their remaining lifetime in the absence of PSA testing.
Thus, a phenomenon analogous to screening-induced overdiag-
nosis may take place as a result of diagnostic testing.
In this study, we examine the relationship between PSA testing
and prostate cancer diagnosis in a residentially defined population
from 1996 to 2002, and estimate the extent to which overdiagnosis
has contributed to the 6% excess in East Anglia.
MATERIALS AND METHODS
Estimation of the population of the Cambridge area
The population of interest was defined by residence using postcode
districts (first three or four characters of the 1998 Postcode
address). Men living in postcode areas CB1 to CB4, which are
completely within the administrative boundaries of Cambridge
City (CC) and South Cambridgeshire (SC), were included. Men
living within the defined postcodes constituted 92% of CC and 72%
of SC total male district populations. This area is hereafter referred
to as the Cambridge area. Assuming homogeneity between the
included and excluded populations, the age profile of the included
population could be estimated. This was the only population for
which individual testing information was available.
Individual PSA testing records from 1996 were available at
Addenbrookes Hospital, which serves the Cambridge area. Using
the NHS number, the laboratory linked its records of PSA tests to
the Eastern Cancer Registry and Information Centre’s (ECRIC)
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area between 1996 and 2002. The linked records made it possible
to identify whether a test was performed before diagnosis, in the
peridiagnostic period (see below) or for monitoring prostate
cancer postdiagnosis. The PSA tests with no match among prostate
cancer registrations were considered not to have led to a cancer
diagnosis.
Statistical analysis
Prediagnosis PSA testing was defined as PSA testing at least 6
months before any diagnosis of prostate cancer. Peridiagnostic
testing was defined as any PSA testing before the date of
pathological diagnosis, including within the 6 months before
diagnosis. Thus, this would include PSA tests that led directly to
the diagnosis.
In the primary analysis, a Poisson regression model was fitted
with cases of prostate cancer and prediagnosis PSA testing status,
adjusting for the effects of age and calendar year. Deviance w
2
statistics were used to determine the significance of the effects of
the variables (prediagnosis PSA testing, age, year) and to examine
the interaction between age and PSA testing, that is, to see whether
the association between PSA testing and prostate cancer diagnosis
differed by age.
In sensitivity analysis, the definition of prediagnosis was relaxed
to include peridiagnosis PSA testing.
For purpose of this study, we define overdiagnosis as the
diagnosis of asymptomatic prostate cancer through PSA testing,
whose lead time is such that the host would have died before
serious clinical problems arose. If the mean sojourn time (lead
time) is M, the probability that a PSA-detected case would have
taken longer than the remaining lifetime to become symptomatic
can be estimated as expð t=MÞwhere t is the expected remaining
lifetime (Duffy et al, 2001; Paci et al, 2004).
Using expected remaining lifetimes for the UK male population
in 2001–2003, and estimates of lead time from the literature, age-
specific probabilities of overdiagnosis were calculated. Applying
these probabilities to the number of cases with prediagnosis
PSA test, the number of overdiagnosed cases and therefore the
proportion of the recent excess cases considered to be over-
diagnosed were estimated. Excess cases refer to prostate cancer
patients whose diagnosis at the time was likely to be attributable to
PSA testing activity.
Analysis was performed using STATA version 7.0. Po0.05 was
considered statistically significant.
RESULTS
PSA tests in the Cambridge area
In the Cambridge area from 1 January 1996 to 31 December 2002
(that is the period during which we had PSA data linked to cancer
registry data), 8894 men had at least one PSA test, of whom 23%
(2053) were 50–59 years, 30% (2701) were 60–69 years and 38%
(3352) were 70–89 years. Sixty-four percent (5722) of men had
repeat peridiagnosis PSA testing. Only 38 of these men with
peridiagnosis PSA testing had a prostate cancer diagnosis. The
crude proportion of men at risk – 40 years or over, with no known
prior diagnosis of prostate cancer – having a PSA test in a given
year increased from 1.4% in 1996 to 5.2% in 2002.
Figure 1 shows the age-standardised testing rate in the
Cambridge area residents from 1996 to 2002.
Excess cases associated with PSA testing
Table 1 gives the number of cases, person-years and incidence
rates of prostate cancer by previous testing status and age. As
expected, increased incidence was observed at older ages. One can
also see the PSA testing rate increasing with age in this table. The
0
1000
2000
3000
4000
5000
6000
1996 1997 1998 1999 2000 2001 2002
Year of testing
 
 
 
 
T
r
u
n
c
a
t
e
d
 
a
g
e
-
s
t
a
n
d
a
r
d
i
s
e
d
(
E
u
r
o
p
e
a
n
)
 
P
S
A
 
t
e
s
t
i
n
g
 
r
a
t
e
 
p
e
r
 
 
 
 
 
 
 
 
 
 
 
1
0
0
0
0
0
 
m
e
n
-
y
e
a
r
s
 
Figure 1 Prostate-specific antigen testing rate per 100000 men-years 40
years or over with no previous cancer diagnosis, Cambridge area, 1996–
2002, standardised using the truncated European Standard Population.
Table 1 Number of prostate cancer registrations, men-years at risk, and incidence rate per 100000 men-years, in men resident in the Cambridge area
during 1996–2002, stratified by existence of a PSA test in this calendar period and before diagnosis
PSA tested PSA not tested
Age group
(years)
No. of
cases
Men-years
at risk
a
Incidence
rate per 100000
men-year
No. of
cases
Men-years
at risk
a
Incidence
rate per 100000
men-year
40–44 0 285 — 0 44784 —
45–49 0 474 — 1 43295 2
50–54 2 880 227 18 41339 44
55–59 3 1178 255 34 32623 104
60–64 3 1323 227 59 26565 222
65–69 7 1385 505 111 22614 491
70–74 7 1231 569 145 19924 728
75–79 5 1060 472 132 15585 847
80–84 3 679 442 98 9755 1005
85–89 2 401 499 50 5191 963
Total 32 8896 360
b 648 261675 248
b
PSA¼prostate-specific antigen.
aDenominator estimates based on testing status at midyear.
bCrude incidence rate.
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years to 72% at age 85–89 years. The crude incidence of registered
prostate cancer was 360 out of 100000 men-years in men who had
a PSA test before diagnosis, and 248 out of 100000 men-years in
men with no prediagnosis PSA test. The increase in reported
incidence was most evident in the age range 50–64 years, with
higher incidence among those not tested at older ages.
The rate ratios (RR) from Poisson regression associated with
PSA testing history are shown in Table 2, both unadjusted and
adjusted for calendar year and age. Unadjusted, there was a
significant 45% increase in risk associated with PSA testing. The
effect of PSA testing was no longer observed when adjusted for age
(age-adjusted RR¼0.86, 95% confidence intervals (CI) 0.60–1.23).
There was heterogeneity by age of the effect of PSA testing
(Po0.001). Analysis separately for age strata 40–64 and 65–89
years showed that PSA testing was associated with more than
three-fold increase in risk (P¼0.001) in the younger groups, and
there was a nonsignificant reduction in risk associated with PSA
testing in the older groups. Thus, neither the unadjusted nor the
age-adjusted effect of PSA testing is ideal. For simplicity we use the
unadjusted effect below.
Estimation of overdiagnosis
Table 3 shows lead time estimates from the literature for screen
detected prostate cancer. The majority of the estimates lie in
the range 5–10 years. We assumed that these would generalise
to cancers detected by PSA testing outside formal screening
programmes. We therefore performed three analyses of lead time,
assuming average sojourn time (duration of the preclinical screen
detectable period) of 5, 7 and 10 years. The age-specific
probabilities of overdiagnosis corresponding to each lead time
and the estimated numbers of overdiagnosed cases are shown in
Tables 4 and 5, respectively.
The number of excess cases among the PSA-tested men was
calculated using the unadjusted RR of 1.45, estimated from the
Poisson regression. For example, for the age group 80–84 years,
the figure of three cases is calculated to be 45% higher than the
incidence would have been in the absence of PSA testing. The
excess is calculated as 3 (3/1.45)¼0.93.
It was estimated that 10 (31%) out of 32 cases were excess cases.
Depending on the assumed lead time of 5, 7 and 10 years, 40, 60
and almost 100%, respectively, of the excess cases were estimated
to be overdiagnosed cases (Table 5).
In a sensitivity analysis, the definition of prediagnosis was
relaxed to peridiagnosis, including any PSA test performed up
to the date of diagnosis. This analysis gave 38 cases with
peridiagnosis PSA. The unadjusted RR of cancer diagnosis in
men with PSA test record vs men with no PSA test record was 1.72
(95% CI 1.24–2.39). The interaction with age was still observed.
The age-specific RR for men younger than 65 years was 4.47 (95%
CI 2.41–8.31) and 0.77 (95% CI 0.53–1.14) for men 65 years or
over. The estimated number of overdiagnosed cases in the
Cambridge area for a 7-year lead time increased from 6 to 8.
DISCUSSION
The proportion of men older than 40 years in the Cambridge area
who had a PSA test has increased from 1.4% in 1996 to 5.2% in
2002. The rate of diagnosis of prostate cancer was 45% higher in
patients with prediagnosis PSA testing. More than half of the cases
with prediagnosis PSA testing are likely to have been over-
diagnosed, that is they would not have been detected clinically in
their lifetime without the PSA testing.
The proportion of men 40 years and over in the Cambridge area
having at least one prediagnosis PSA test in a given calendar year
is comparable to the national figures. In the UK, a survey of the GP
Table 2 Year of testing and age adjusted RR and age-specific RR and
95% CI for prostate cancer diagnosis in PSA tested vs nontested men
resident in Cambridge area, 1996–2002
RR 95% CI
Adjusting variable
None 1.45 1.02–2.07
Year 1.39 0.98–1.99
Age group (two categories) 0.86 0.60–1.23
Year+age group 0.83 0.58–1.19
Interaction variable
Age group (years)
40–64 3.25 1.59–6.67
65–89 0.69 0.46–1.04
CI¼confidence intervals; PSA¼prostate-specific antigen RR¼rate ratios.
Table 3 Estimated lead times for screen detected prostate cancer
Paper
Age
range
Lead
time
(years) Study setting
Tornblom et al (2004) 55–70 4.5 Population-based cohort study
Draisma et al (2003) 55 12.3 MISCAN model, based on estimates
derived from the European
randomised study of screening for
prostate cancer
60 11.0
65 9.5
70 7.7
75 6.0
Etzioni et al (2002) 60–84 5.0 Modelling
Auvinen et al (2002) 7.0 Randomised trial (Finland)
Hugosson et al (2000) 67 7.0 Nested case–control study (Sweden)
McGregor et al (1998) 50–70 12.0 Modelling
Gann et al (1995) 40–84 5.5 Nested case–control study (USA)
Table 4 Expected remaining lifetime and probability of overdiagnosis
based on lead times of 5, 7 and 10 years
Age
group
(years)
Expected
remaining
lifetime
(years)
Probability of
overdiagnosis
(%)
Probability of
overdiagnosis
(%)
Probability of
overdiagnosis
(%)
M
a¼5 years M
a¼7 years M
a¼10 years
40–44 35.8 0.08 0.6 2.8
45–49 31.2 0.2 1.2 4.4
50–54 26.7 0.5 2.2 6.9
55–59 22.4 1.1 4.1 10.6
60–64 18.4 2.5 7.2 15.9
65–69 14.7 5.3 12.2 23.0
70–74 11.4 10.2 19.6 32.0
75–79 8.6 17.9 29.3 42.3
80–84 6.3 28.4 40.7 53.3
85–89 4.5 40.7 52.6 63.8
Based on lifetable on UK males based on data for the years 2001–2003, produced by
the Government Actuary’s Department.
aM-mean sojourn time B lead time.
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record of prostate cancer having at least one PSA test increased
from 1.4% in 1994 to 3.5% in 1999 (Melia and Moss, 2001).
The relatively small percentage of prostate cancer cases, 5.6%
(38 out of 680), between 1996 and 2002 with a recorded
prediagnosis or peridiagnosis PSA test is surprising. However,
the estimated number of excess cases (252) in East Anglia based on
the results here is very close to the number estimated (289) based
on age-period-cohort analysis reported in our previous study
(Pashayan et al, 2006). There may be minor faults in record linkage
between the cancer registry and the laboratory records for PSA
testing and subsequent underestimation in the estimates of excess
diagnosis associated with PSA testing. However, in this setting with
a relatively small number of men actually receiving PSA tests, the
estimates are at least plausible.
In the Cambridge area, prostate cancer was detected in only
0.4% (38 out of 8894) of men tested for PSA. Studies of
screening for prostate cancer have shown widely varying detection
proportions, from 0.2% (Perrin et al, 1991) to 4.8% (Smith
and Catalona, 1994). Results vary according to the screening
methods used (PSA, PSA with and without digital rectal
examination, PSA with and without transrectal ultrasound), age
of the participants, sample sizes, PSA cutoff points employed to
determine further tests (Selley et al, 1997) and biopsy procedures
and policies (Emiliozzi et al, 2004). Each of these factors can
affect the detection proportion. Also, of course, the results in
the literature pertain to population screening rather than
increased diagnostic availability, as in this study. The much
larger rates of detection in the screening studies are also partly due
to the fact that rates have been reported for prevalence screen
rather than for incidence screen. In the years following the
prevalence screen, the average incidence rate will be smaller. In
Ciatto et al (2005), prostate cancer was diagnosed in 1.75% of
patients tested for PSA at the first screening and in 0.65% at the
second.
In this study, a history of PSA testing was associated with a 45%
excess risk of prostate cancer diagnosis. A randomised controlled
study on screening effectiveness in Sweden showed that men
undergoing active screening had a 2.6-fold increased risk of being
diagnosed with prostate cancer during the 7-year study period
(Hugosson et al, 2004). A study from Florence showed 66%
increased risk of prostate cancer diagnosis in men having PSA
screening over 9-year period (Ciatto et al, 2005). These results
from screening tests suggest that the effect of prediagnosis PSA
testing on incidence is more modest than that of formal population
screening.
The unadjusted RR of 1.45 was used for the calculation of PSA-
induced excess registration. This is not ideal. However, as there is
age heterogeneity of the effect, the age-adjusted effect would be
even less appropriate. The ideal would be to use age-specific RRs.
However, the small number of cases in individual age groups
would render these unstable. It is hoped that in future, larger
studies with individual PSA data will be able to produce age-
specific estimates.
The small numbers of PSA-exposed men in this study means
that there is a considerable uncertainty in our estimates. We have
not produced an age-specific or age-adjusted overdiagnosis
estimate partly because of the small numbers and partly because
of the interaction of the PSA effect with age, whereby the excess is
observed at younger ages. A high excess at younger ages usually
means that a standardised ratio will tend to be large. If we had
sufficient data to estimate the age-specific excesses with precision,
the overall excess might be larger than the unadjusted estimate.
Within the age structure of the study population, approximately
60% of the observed excess cases in the PSA-tested group are
estimated to be overdiagnosed. These estimates pertain essentially
to increased diagnostic use rather than population screening. In
the latter case both excess incidence and overdiagnosis would be
larger.
In this study, 12–31% of the cases, with a record of prediagnosis
PSA, were estimated to be overdiagnosed cases. Etzioni et al
(2002), using simulation, estimated overdiagnosis of 29–44% in
60–84 year-old men undertaking PSA screening. This estimation is
dependent on the lead time and the remaining lifetime (which
depends on the age of the individual). The lead time for an
individual PSA detected case is a well-defined concept. It is the
difference between the time the tumour is diagnosed as a result
of PSA testing and the time it would have been diagnosed in the
absence of PSA testing. It is difficult to estimate the lead time in
the absence of an organised screening programme. In this study,
an average of 7 years, which is typically reported in the literature,
was assumed. It may be that because the situation in East Anglia is
not one of formal screening, the earlier detection as a result of
more widespread use of PSA gives a shorter lead time. Use of
longer (10 years) and shorter (5 years) lead times made minor
differences to the estimates.
Extrapolation of the Cambridge area findings to East Anglia
showed that a 1.6% {(78/(252)*5.3%} excess of cases predicted for
1996–2000 could be attributed to PSA testing, which is around a
quarter of the 6%, total excess of cases, estimated in our previous
study. Approximately, 1% of all estimated cases in East Anglia
would be classified as overdiagnosed. Thus, a majority of the
recent excess is not explained by PSA testing.
In conclusion, this study shows that a substantial minority of the
observed excess of cases in recent years is likely to be due to PSA
testing. A majority of the observed excess in the PSA-tested group
is estimated to be overdiagnosis. This, however, is a very small
minority of the total number of cases diagnosed. Further
quantification of the overdiagnosis will result from continued
surveillance and from linkage of incidence to testing in other
hospitals.
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Table 5 Estimated number of overdiagnosed cases using lead times of 5, 7 and 10 years, and number of excess cases for patients diagnosed in the
Cambridge area from 1996–2002
Age
group
(years)
No. of cases
with prediagnosis
PSA test
No. of
excess cases
No. of overdiagnosed
cases (if lead time¼5 years)
No. of overdiagnosed cases
(if lead time¼7 years)
No. of overdiagnosed
cases (If lead time¼10 years)
40–64 8 2.48 0.12 0.38 0.94
65–74 14 4.34 1.08 2.23 3.85
75–89 10 3.10 2.56 3.73 5.00
Total 32 9.92 3.74 6.34 9.77
PSA¼prostate-specific antigen.
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